Patients in both studies were treated with ICI therapy (with anti-PD-1 or anti-CTLA4) and were divided as responders (17 melanoma and 6 BCC) and non-responders (31 melanoma and 5 BCC) according to RECIST criteria. This evidence concerns the gene CTLA4 and melanoma.